What trans-resveratrol is, what the SIRT1 research does and doesn't show in people, the doses used in human trials and what's known about pairing it with NMN.
Trans-resveratrol is the form of resveratrol used in most research. In lab studies it activates SIRT1, one of the sirtuin proteins linked to aging, but oral resveratrol is broken down quickly in the body and direct SIRT1 activation in people is unproven. Human trials (typically 150 to 1,000 mg a day) show small, inconsistent effects, and no human study shows it slows aging.
Resveratrol exists as two stereoisomers: trans-resveratrol and cis-resveratrol. These are two shapes of the same molecule. Trans-resveratrol is the more stable form and the one used in most lab and human research.
Choose a product that states how much trans-resveratrol it contains. A label that only says "resveratrol" or lists a plant extract without a trans-resveratrol amount makes the dose hard to judge; a batch Certificate of Analysis can confirm it.
Sirtuins (SIRT1-7) are a family of proteins involved in cellular regulation, DNA repair, metabolic control and stress resistance. They are NAD+-dependent — they require NAD+ as a co-substrate to function. In lab studies resveratrol increases SIRT1 activity, though how directly it does so has been debated, and whether this happens at the doses people take is unproven.
Because sirtuins need NAD+, some people pair resveratrol with an NAD+ precursor such as NMN, which raises blood NAD+ in small human trials. The idea is plausible on paper, but no human trial has shown that the combination works better than either alone, or that either one slows aging. On human outcomes so far, a 2024 meta-analysis of resveratrol trials in metabolic syndrome found lower blood pressure, no change in HDL cholesterol or waist size and higher triglycerides, and described the results as borderline.